Evidence map›Paper›PMID 27798498›Full record

ReviewCurrent opinion in infectious diseases2017

HIV-associated neurocognitive disorder.

David B Clifford

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Special Issue "Mechanisms of Neurotoxicity".International journal of molecular sciences · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David B CliffordWashington University in St Louis, 660 South Euclid Avenue, St Louis, Missouri, USA.
Washington University in St. Louis · US

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Vanderbilt HIV Clinical Trials Unit (CTU)UM1AI069439 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David W Haas, Spyros A Kalams · 2012 to 2026
$33.1M
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIAU01AG042791 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2013 to 2018
$8.9M
WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNITUM1AI069495 · NIAID · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 2012 to 2013
$2.9M
Frailty and Brain Integrity in Older HIV-infected IndividualsR01NR014449 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2013 to 2017
$2.4M
Washington University Network of Excellence in Neuroscience Clinical Trials SiteU10NS077384 · NINDS · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 2011 to 2017
$1.9M
NEUROIMAGING AND NEUROBEHAVIORAL BASIS OF RISKY DECISION-MAKING IN ADOLESCENTSR01NR012907 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2011 to 2015
$1.9M
THE EFFECTS OF AGE AND HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON BRAIN FUNCTIONR01NR012657 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2010 to 2014
$1.9M
NCATS NIH HHS UL1 TR000448NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069495NIA NIH HHS U01 AG042791NINDS NIH HHS U10 NS077384NINR NIH HHS R01 NR012657NINR NIH HHS R01 NR012907NINR NIH HHS R01 NR014449
6 · The paper itself

Abstract

purpose of reviewHIV-associated neurocognitive disease is the most active topic for neuroAIDS investigations at present. Although impairment is mild in patients successfully treated with modern antiviral regimens, it remains an ongoing problem for HIV patients. It is important to update the emerging research concerning HIV-associated neurocognitive disease. RECENT

findingsThe virus enters the brain during acute infection, with evidence for abnormal functioning that may occur early and often persists. Direct relationships with ongoing viral infection continue to be monitored, but chronic inflammation often associated with monocytes and macrophages appears to be the most likely driver of cognitive dysfunction. Appreciation for cerebrovascular disease as a significant comorbidity that is associated with cognitive deficits is increasing. Neuroimaging is actively being developed to address detection and measurement of changes in the brain. Optimal combined antiretroviral treatment therapy has vastly improved neurologic outcomes, but so far has not been demonstrated to reverse the remaining mild impairment. Inflammatory and vascular mechanisms of cerebral dysfunction may need to be addressed to achieve better outcomes. SUMMARY: Ongoing research is required to improve neurological outcomes for persons living with HIV. It is likely that interventions beyond antiviral approaches will be required to control or reverse HIV-associated neurocognitive disease.

Indexed as

Anti-Retroviral AgentsBrainChronic DiseaseHIV InfectionsHumansInflammationMonocytesNeurocognitive DisordersAnti-Retroviral Agents

Identifiers

PMID27798498
PMCPMC5382956
OpenAlexW2542043731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.